Author:
Mangum Blake R.,Pogue Jason M.,Barber Katie E.
Abstract
Abstract
Purpose of Review
Antimicrobial resistance is a growing threat to public health, leading to millions of antibiotic-resistant infections and thousands of deaths annually in the USA. One concerning issue is the rise of extended-spectrum beta-lactamase (ESBL)–producing Enterobacterales. Current treatments often involve intravenous carbapenems, leading to prolonged hospital stays and financial burdens.
Recent Findings
To address this, new oral penem agents, tebipenem and sulopenem, are being investigated. They are administered as prodrugs, enhancing bioavailability before becoming active in the gastrointestinal tract, potentially treating multidrug-resistant infections in outpatient settings. Despite promise in clinical trials, challenges exist, such as tebipenem’s renal excretion, requiring dose adjustments for kidney dysfunction. Additionally, sulopenem failed noninferiority margins in trials, and neither drug has established susceptibility testing standards.
Summary
Tebipenem and sulopenem offer potential oral solutions for antimicrobial resistance, especially in urinary tract infections, but further research is needed for optimal dosing and susceptibility testing.
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. CDC. Antibiotic resistance threats in the United States, 2019. Centers for Disease Control and Prevention. National Center for Emerging Zoonotic and Infectious Diseases (U.S.). 2019. https://doi.org/10.15620/cdc:82532.
2. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious diseases Society of America 2023 Guidance on the treatment of antimicrobial resistant gram-negative infections. Clin Infect Dis. 2023. https://doi.org/10.1093/cid/ciad428.
3. Kassakian SZ, Mermel LA. Changing epidemiology of infections due to extended spectrum beta-lactamase producing bacteria. Antimicrob Resist Infect Control. 2014;3(1):9. https://doi.org/10.1186/2047-2994-3-9.
4. Fluoroquinolone-resistant E.coli. Centers for Disease Control and Prevention. Antibiotic Resistance.A.R. & Patient Safety Portal. Antibiotic resistance and patient safety portal. Accessed October 26, 2023. https://arpsp.cdc.gov/profile/antibiotic-resistance?tab=antibiotic-resistance.
5. Hospital adjusted expenses per inpatient day | KFF. Accessed August 2, 2023. https://www.kff.org/health-costs/state-indicator/expenses-per-inpatient-day/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D.